title: The neuroprotective effect of erythropoietin on experimental Parkinson model in rats.
abstract: Dopaminergic neuronal loss in Parkinson's disease (PD) results from oxidative stress, neuroinflammation and excitotoxicity. Because erythropoietin (EPO) has been shown to have antioxidant, anti-inflammatory and neuroprotective effects in many previous studies, present study was designed to evaluate the effect of EPO on rotenone-induced dopaminergic neuronal loss. The rats in which PD was induced by stereotaxical infusion of rotenone showed increased MDA and TNF-alpha levels and decreased HVA levels. On the other hand, EPO treatment resulted in markedly decreased MDA and TNF-alpha levels and increased HVA levels. EPO treatment in rotenone-infusion group resulted in improvement of striatal neurodegeneration and a significant increase in decreased total number of neurons and immunohistochemical TH positive neurons. Results of the present study demonstrate the neuroprotective, anti-inflammatory and antioxidant effects of EPO in a rotenone-induced neurodegenerative animal model.
authors.affiliation: Department of Physiology, Gaziosmanpasa University Faculty of Medicine, Tokat, Turkey.
authors.forename: Oytun
authors.initials: O
authors.lastname: Erbaş
authors.affiliation: Giresun State Hospital, Giresun, Turkey.
authors.forename: Bilge Piri
authors.initials: BP
authors.lastname: Çınar
authors.affiliation: Department of Neurology, Turhal State Hospital, Tokat, Turkey. Electronic address: solmaz.volkan@yahoo.com.
authors.forename: Volkan
authors.initials: V
authors.lastname: Solmaz
authors.affiliation: Department of Histology and Embryology, Ege University School of Medicine, Izmir, Turkey.
authors.forename: Türker
authors.initials: T
authors.lastname: Çavuşoğlu
authors.affiliation: Department of Histology and Embryology, Ege University School of Medicine, Izmir, Turkey.
authors.forename: Utku
authors.initials: U
authors.lastname: Ateş
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D000975:Antioxidants / Q000008:administration & dosage; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D059290:Dopaminergic Neurons / Q000187:drug effects* / Q000378:metabolism; D004921:Erythropoietin / Q000008:administration & dosage*; D008297:Male; D008315:Malondialdehyde / Q000032:analysis; D009043:Motor Activity / Q000187:drug effects; D018696:Neuroprotective Agents / Q000008:administration & dosage*; D020734:Parkinsonian Disorders / Q000139:chemically induced / Q000188:drug therapy*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012402:Rotenone; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis; D014446:Tyrosine 3-Monooxygenase / Q000032:analysis
chemical_list: D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D018696:Neuroprotective Agents; D014409:Tumor Necrosis Factor-alpha; D012402:Rotenone; D004921:Erythropoietin; D008315:Malondialdehyde; D014446:Tyrosine 3-Monooxygenase
keywords: Erythropoietin; Inflammation; Neuronal cell loss; Neuroprotection; Rotenone